BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 17264187)

  • 1. The effect of sibutramine on energy expenditure and body composition in obese adolescents.
    Van Mil EG; Westerterp KR; Kester AD; Delemarre-van de Waal HA; Gerver WJ; Saris WH
    J Clin Endocrinol Metab; 2007 Apr; 92(4):1409-14. PubMed ID: 17264187
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Use of sibutramine in obese mexican adolescents: a 6-month, randomized, double-blind, placebo-controlled, parallel-group trial.
    García-Morales LM; Berber A; Macias-Lara CC; Lucio-Ortiz C; Del-Rio-Navarro BE; Dorantes-Alvárez LM
    Clin Ther; 2006 May; 28(5):770-82. PubMed ID: 16861099
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Use of sibutramine in overweight adult hispanic patients with type 2 diabetes mellitus: a 12-month, randomized, double-blind, placebo-controlled clinical trial.
    Sánchez-Reyes L; Fanghänel G; Yamamoto J; Martínez-Rivas L; Campos-Franco E; Berber A
    Clin Ther; 2004 Sep; 26(9):1427-35. PubMed ID: 15531005
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Effects of sibutramine on blood glucose and lipids, body fat mass and insulin resistance in obese patients: a multi-center clinical trial].
    Tong NW; Ran XW; Li QF; Tang BD; Li R; Yang FY; Liu YP; Li XJ
    Zhonghua Nei Ke Za Zhi; 2005 Sep; 44(9):659-63. PubMed ID: 16202254
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Second phase of a double-blind study clinical trial on Sibutramine for the treatment of patients suffering essential obesity: 6 months after treatment cross-over.
    Fanghänel G; Cortinas L; Sánchez-Reyes L; Berber A
    Int J Obes Relat Metab Disord; 2001 May; 25(5):741-7. PubMed ID: 11360159
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Six-month treatment of obesity with sibutramine 15 mg; a double-blind, placebo-controlled monocenter clinical trial in a Hispanic population.
    Cuellar GE; Ruiz AM; Monsalve MC; Berber A
    Obes Res; 2000 Jan; 8(1):71-82. PubMed ID: 10678261
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Behavior therapy and sibutramine for the treatment of adolescent obesity: a randomized controlled trial.
    Berkowitz RI; Wadden TA; Tershakovec AM; Cronquist JL
    JAMA; 2003 Apr; 289(14):1805-12. PubMed ID: 12684359
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of sibutramine treatment in obese adolescents: a randomized trial.
    Berkowitz RI; Fujioka K; Daniels SR; Hoppin AG; Owen S; Perry AC; Sothern MS; Renz CL; Pirner MA; Walch JK; Jasinsky O; Hewkin AC; Blakesley VA;
    Ann Intern Med; 2006 Jul; 145(2):81-90. PubMed ID: 16847290
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sibutramine is safe and effective for weight loss in obese patients whose hypertension is well controlled with angiotensin-converting enzyme inhibitors.
    McMahon FG; Weinstein SP; Rowe E; Ernst KR; Johnson F; Fujioka K;
    J Hum Hypertens; 2002 Jan; 16(1):5-11. PubMed ID: 11840224
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of obese adolescents with sibutramine: a randomized, double-blind, controlled study.
    Godoy-Matos A; Carraro L; Vieira A; Oliveira J; Guedes EP; Mattos L; Rangel C; Moreira RO; Coutinho W; Appolinario JC
    J Clin Endocrinol Metab; 2005 Mar; 90(3):1460-5. PubMed ID: 15613431
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effect of sibutramine on energy expenditure and appetite during chronic treatment without dietary restriction.
    Hansen DL; Toubro S; Stock MJ; Macdonald IA; Astrup A
    Int J Obes Relat Metab Disord; 1999 Oct; 23(10):1016-24. PubMed ID: 10557021
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cardiovascular effects of sibutramine in the treatment of obese adolescents: results of a randomized, double-blind, placebo-controlled study.
    Daniels SR; Long B; Crow S; Styne D; Sothern M; Vargas-Rodriguez I; Harris L; Walch J; Jasinsky O; Cwik K; Hewkin A; Blakesley V;
    Pediatrics; 2007 Jul; 120(1):e147-57. PubMed ID: 17576783
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of sibutramine for weight loss in obese patients with hypertension well controlled by beta-adrenergic blocking agents: a placebo-controlled, double-blind, randomised trial.
    Sramek JJ; Leibowitz MT; Weinstein SP; Rowe ED; Mendel CM; Levy B; McMahon FG; Mullican WS; Toth PD; Cutler NR
    J Hum Hypertens; 2002 Jan; 16(1):13-9. PubMed ID: 11840225
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety comparative evaluation of orlistat and sibutramine treatment in hypertensive obese patients.
    Derosa G; Cicero AF; Murdolo G; Piccinni MN; Fogari E; Bertone G; Ciccarelli L; Fogari R
    Diabetes Obes Metab; 2005 Jan; 7(1):47-55. PubMed ID: 15642075
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term maintenance of weight loss with sibutramine in a GP setting following a specialist guided very-low-calorie diet: a double-blind, placebo-controlled, parallel group study.
    Mathus-Vliegen EM;
    Eur J Clin Nutr; 2005 Aug; 59 Suppl 1():S31-8; discussion S39. PubMed ID: 16052193
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effect of sibutramine intake on resting and exercise physiological responses.
    Rotstein A; Inbar O; Vaisman N
    Ann Nutr Metab; 2008; 52(1):17-23. PubMed ID: 18230966
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of sibutramine-induced weight loss on cardiovascular system in obese subjects.
    de Simone G; Romano C; De Caprio C; Contaldo F; Salanitri T; di Luzio Paparatti U; Pasanisi F
    Nutr Metab Cardiovasc Dis; 2005 Feb; 15(1):24-30. PubMed ID: 15871847
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A randomized, double-blind, placebo-controlled study of sibutramine in the treatment of binge-eating disorder.
    Appolinario JC; Bacaltchuk J; Sichieri R; Claudino AM; Godoy-Matos A; Morgan C; Zanella MT; Coutinho W
    Arch Gen Psychiatry; 2003 Nov; 60(11):1109-16. PubMed ID: 14609886
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Psychobehavioral and nutritional predictors of weight loss in obese women treated with sibutramine.
    Hainer V; Kunesova M; Bellisle F; Hill M; Braunerova R; Wagenknecht M
    Int J Obes (Lond); 2005 Feb; 29(2):208-16. PubMed ID: 15583700
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Sibutramine, an upcoming drug for weight loss acting on energy consumption and energy expenditure].
    Astrup A
    Acta Med Austriaca; 1998; 25(4-5):146-9. PubMed ID: 9879391
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.